CEO
InhaTarget Therapeutics
The startup develops an inhalable dry powder formulation specifically for lung cancer treatment, bridging the gap between localized and systemic therapies. This approach provides patients with targeted medication that enhances the management of severe and chronic respiratory diseases.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$10.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops an inhalable dry powder formulation specifically for lung cancer treatment, bridging the gap between localized and systemic therapies. This approach provides patients with targeted medication that enhances the management of severe and chronic respiratory diseases.